Skip to main content
Blueprint Medicines Corporation (BPMC)
Jul 18, 2025 - BPMC was delisted (reason: acquired by SNY)
129.46
0.00 (0.00%)
Inactive · Last trade price on Jul 17, 2025

Blueprint Medicines Revenue

Blueprint Medicines had revenue of $149.41M in the quarter ending March 31, 2025, with 55.45% growth. This brings the company's revenue in the last twelve months to $562.12M, up 99.19% year-over-year. In the year 2024, Blueprint Medicines had annual revenue of $508.82M with 104.04% growth.

Revenue (ttm)
$562.12M
Revenue Growth
+99.19%
P/S Ratio
n/a
Revenue / Employee
$820,615
Employees
649
Market Cap
n/a

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024508.82M259.44M104.04%
Dec 31, 2023249.38M45.34M22.22%
Dec 31, 2022204.04M23.96M13.30%
Dec 31, 2021180.08M-613.66M-77.31%
Dec 31, 2020793.74M727.22M1,093.37%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

BPMC News

More News